PREVU(x) Data to be Presented at Arteriosclerosis, Thrombosis and Vascular Biology Conference
March 27 2006 - 10:15AM
PR Newswire (US)
TORONTO, March 27 /PRNewswire-FirstCall/ -- Predictive medicine
company PreMD Inc. (TSX: PMD; Amex: PME) today announced that a
scientific abstract featuring PREVU(x) Point of Care (POC) Skin
Sterol Test has been accepted for presentation at the American
Heart Association's 7th Annual Conference on Arteriosclerosis,
Thrombosis and Vascular Biology, in Denver, Colorado, April 27 -
29, 2006. The abstract accepted for presentation is Skin tissue
cholesterol and C-reactive protein are associated with increased
prevalence of metabolic syndrome in high-risk subjects by Julie
Gillett, William Osler Health Center, Brampton, ON; Greg Pearce,
Innovative Data Resources, Asheville, NC; and Michael Evelegh,
Milan Gupta, McMaster University, Hamilton, ON. The
Arteriosclerosis, Thrombosis and Vascular Biology conference
focuses on developing new research opportunities in
arteriosclerosis, thrombosis and vascular biology to address
prevention and improve methods for diagnosis and treatment of heart
disease. About PreMD PreMD Inc. is a world leader in predictive
medicine, dedicated to developing rapid, non-invasive tests for the
early detection of life- threatening diseases. PreMD's
cardiovascular products, which are branded as PREVU(x) Skin Sterol
Test, are licensed worldwide to McNeil Consumer Healthcare. The
company's cancer tests include ColorectAlert(TM), LungAlert(TM) and
a breast cancer test. PreMD's head office is located in Toronto,
and its research and product development facility is at McMaster
University in Hamilton, Ontario. For further information, please
visit http://www.premdinc.com/. For more information about
PREVU(x), please visit http://www.prevu.com/ or call 1-866-283-8328
(North America) or 00-800-8283-8328 (Europe), or email . This press
release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could
cause the Company's actual results to differ materially from those
in the forward- looking statements. Such risks and uncertainties
include, among others, the successful development or marketing of
the Company's products, the competitiveness of the Company's
products if successfully commercialized, the lack of operating
profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies,
product liability, reliance on third-party manufacturers, the
ability of the Company to take advantage of business opportunities,
uncertainties related to the regulatory process, and general
changes in economic conditions. In addition, while the Company
routinely obtains patents for its products and technology, the
protection offered by the Company's patents and patent applications
may be challenged, invalidated or circumvented by our competitors
and there can be no guarantee of our ability to obtain or maintain
patent protection for our products or product candidates. Investors
should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned not to rely on these
forward-looking statements. PreMD is providing this information as
of the date of this press release and does not undertake any
obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or
otherwise. (x)Trademark DATASOURCE: PreMD Inc. CONTACT: Sarah
Borg-Olivier, Director, Communications, Tel: (416) 222-3449 ext.
27, Email:
Copyright